Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management
- PMID: 31868768
- DOI: 10.1097/CRD.0000000000000281
Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management
Abstract
Primary aldosteronism remains a leading cause of secondary hypertension, and its diagnosis and management continue to pose a challenge for clinicians. In this article, we review the diagnosis of primary aldosteronism along with its cardiovascular manifestations. Treatment is described depending on the diagnostic outcome, focusing on medical management with mineralocorticoid receptor antagonists and unilateral adrenalectomy. Although screening and diagnosing hyperaldosteronism follows well-known algorithms, in practice, physicians may find difficulty establishing the best course of action due to complexity in testing and confirming laterality of aldosterone production by the adrenals. Recognizing and treating primary aldosteronism requires a multidisciplinary approach with primary care physicians, cardiologists, endocrinologists, and radiologists working collaboratively.
References
-
- Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med. 1956;44:1–15.
-
- Käyser SC, Dekkers T, Groenewoud HJ, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101:2826–2835.
-
- Funder JW. Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control. 2013;6:129–138.
-
- Masilamani S, Kim GH, Mitchell C, et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest. 1999;104:R19–R23.
-
- Feraille E, Dizin E. Coordinated control of ENaC and Na+,K+-ATPase in renal collecting duct. J Am Soc Nephrol. 2016;27:2554–2563.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
